Sum Up The Pieces: JPSE Could Be Worth $57

The JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) is projected to have a 13.98% upside, with an implied analyst target price of $56.95 from its recent $49.97 trading price, based on the weighted average of its underlying holdings' 12-month forward analyst targets. This potential is significantly driven by key constituents such as Harmony Biosciences Holdings Inc (HRMY), Crescent Energy Co (CRGY), and Castle Biosciences Inc (CSTL), which analysts anticipate could see upsides of 67.71%, 64.74%, and 53.08%, respectively.

Analysis

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the JPMorgan Diversified Return U.S. Small Cap Equity ETF (Symbol: JPSE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $56.95 per unit. With JPSE trading at a recent price near $49.97 per unit, that means that analysts see 13.98% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of JPSE's underlying holdings with notable upside to their analyst target prices are Harmony Biosciences Holdings Inc (Symbol: HRMY), Crescent Energy Co (Symbol: CRGY), and Castle Biosciences Inc (Symbol: CSTL). Although HRMY has traded at a recent price of $26.56/share, the average analyst target is 67.71% higher at $44.55/share. Similarly, CRGY has 64.74% upside from the recent share price of $9.16 if the average analyst target price of $15.09/share is reached, and analysts on average are expecting CSTL to reach a target price of $36.11/share, which is 53.08% above the recent price of $23.59. Below is a twelve month price history chart comparing the stock performance of HRMY, CRGY, and CSTL: Below is a summary table of the current analyst target prices discussed above: | Name | Symbol | Recent Price | Avg. Analyst 12-Mo. Target | % Upside to Target | |---|---|---|---|---| | JPMorgan Diversified Return U.S. Small Cap Equity ETF | JPSE | $49.97 | $56.95 | 13.98% | | Harmony Biosciences Holdings Inc | HRMY | $26.56 | $44.55 | 67.71% | | Crescent Energy Co | CRGY | $9.16 | $15.09 | 64.74% | | Castle Biosciences Inc | CSTL | $23.59 | $36.11 | 53.08% | Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » Also see: Real Estate Dividend Stock List Top Ten Hedge Funds Holding BKC PSEC Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) currently trades at $49.97, with an implied analyst target price of $56.95, suggesting a 13.98% upside for the ETF. This projection is derived from the weighted average of 12-month forward analyst target prices across its underlying holdings. This represents a potentially attractive return profile based on current consensus. Key contributors to this potential upside include Harmony Biosciences (HRMY), Crescent Energy (CRGY), and Castle Biosciences (CSTL). HRMY analysts project a 67.71% increase to $44.55 from its recent $26.56, CRGY an estimated 64.74% upside to $15.09, and CSTL a 53.08% upside to $36.11. These three stocks demonstrate significant individual upside according to current analyst consensus, driving the ETF's implied target. However, the analysis explicitly raises concerns regarding the validity and timeliness of these price targets, warning that they could be overly optimistic or outdated. High price targets, if not supported by recent developments, could precede downgrades, necessitating further investor due diligence.

Key Decisions for Investors

• Investors should conduct thorough due diligence on the fundamental outlook and recent developments of JPSE's high-upside underlying holdings, such as HRMY, CRGY, and CSTL.
• Evaluate the recency and specific rationales behind the analyst target prices for these individual stocks, given the article's caution about potential over-optimism or outdated estimates.